Litigation Details for BAUSCH HEALTH IRELAND LIMITED v. PADAGIS ISRAEL PHARMACEUTICALS LTD (D.N.J. 2020)

✉ Email this page to a colleague

BAUSCH HEALTH IRELAND LIMITED v. PADAGIS ISRAEL PHARMACEUTICALS LTD (D.N.J. 2020)

Docket	⤷ Start Trial	Date Filed	2020-05-01
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Patents	10,251,895; 10,426,787; 10,478,502; 8,809,307
Link to Docket	External link to docket

Small Molecule Drugs cited in BAUSCH HEALTH IRELAND LIMITED v. PADAGIS ISRAEL PHARMACEUTICALS LTD

The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial and ⤷ Start Trial .

Details for BAUSCH HEALTH IRELAND LIMITED v. PADAGIS ISRAEL PHARMACEUTICALS LTD (D.N.J. 2020)

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2020-05-01	144	Order on Motion for Summary Judgment	Bausch owns U.S. Patent Nos. 10,251,895 (“the ’895 patent”) and 10,426,787 (the “’787 patent,” and together…States Patent Application No. 15/173,961 ultimately issued as the ’895 patent. United States Patent Application…together with the ’895 patent, the “Combination Patents”). For the reasons that follow, Plaintiffs’ motion…903,785 ultimately issued as the ’787 patent. The Combination Patents have the same inventors, both claim…8362 Patent Application No. 15/903,785, which was filed on June 18, 2015, and the two patents have	External link to document
2020-05-01	196	Order on Motion in Limine AND Order on Motion in Limine AND Order on Motion in Limine AND Order on Motion in Limine AND Order on Motion in Limine AND Order on Motion in Limine	Bausch owns U.S. Patent Nos. 10,251,895 (“the ’895 patent”), 10,426,787 (“the ’787 patent,” and together…together with the ’895 patent, the “Combination Patents”), 8,809,307 (“the ’307 patent”) and 10,478,502 (…reduction . . .” (Claim 1 of the ‘787 patent; claim 1 of the ‘895 patent.) The language of the relevant…produces” test has a foundation in either the patents or patent law; this Court rejects Defendants’ argument…starring role in the patent specifications, as IDP-118 has in the Combination Patents. There is nothing	External link to document
2020-05-01	246	Opinion	Bausch owns U.S. Patent Nos. 10,251,895 (“the ’895 patent”), 10,426,787 (“the ’787 patent,” and together…the ’502 patent,” and together with the ’307 patent, the “HP Patents”). All four patents are listed…the ’295 patent; 2) Blum, the ’295 patent and the ’566 patent; and 3) Blum, the ’295 patent, and JP…together with the ’895 patent, the “Combination Patents”), 8,809,307 (“the ’307 patent”) and 10,478,502 … of the’895 and ’787 Patents. ’895 Patent, at 11:30–20:10; ’787 Patent, at 11:30–20:8.	External link to document
2020-05-01	75	Opinion	concerning the ’307 Patent, the ’502 Patent, U.S. Patent Nos. 10,251,895 (the “’895 Patent”) and 10,426,787…infringement of U.S. Patent Nos. 8,809,307 (the “’307 Patent”) and 10,478,502 (the “’502 Patent”) through Padagis…prosecution of a patent application has a duty of candor and good faith in dealing with the [Patent] Office, …and ’787 patents being declared invalid. Padagis therefore seeks a judgment that these patents are unenforceable… Bryhali, wherein Padagis alleged that these patents are invalid, unenforceable, and/or will not be	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Litigation Summary and Analysis: BAUSCH HEALTH IRELAND LIMITED v. PADAGIS ISRAEL PHARMACEUTICALS LTD. | 2:20-cv-05426-SRC-CLW

Last updated: January 29, 2026

Executive Summary

This case involves patent infringement allegations filed by Bausch Health Ireland Limited against Padagis Israel Pharmaceuticals Ltd. in the District of New Jersey. The crux of the litigation centers around alleged infringement of patents related to ophthalmic pharmaceutical compositions. The case, initiated in 2020, underscores issues of patent validity, claim scope, and potential market impact for generic ophthalmic medications.

Case Overview

Parties

| Plaintiff | Bausch Health Ireland Limited | A pharmaceutical company specializing in ophthalmic drugs, with patents related to drug formulations. | | Defendant | Padagis Israel Pharmaceuticals Ltd. | Supposed manufacturer and seller of generic ophthalmic products potentially infringing on the patents. |

Patent Involved

Litigation Timeline & Key Events

Date	Event	Details
September 2020	Complaint Filed	Bausch alleges Padagis infringes its patents by manufacturing generic equivalents.
October 2020	Preliminary Injunction Motion	Bausch requests an injunction to prevent sale of alleged infringing products.
December 2020	Response & Discovery Begins	Padagis contests patent validity, seeks to dismiss or limit claims.
June 2021	Markman Hearing	Court interprets patent claim language relevant to infringement analysis.
October 2021	Expert Reports Submitted	Technical analyses submitted regarding patent scope and product similarities.
March 2022	Summary Judgment Motions Filed	Both parties seek ruling on infringement and patent validity.
June 2022	Court Ruling	Court denies preliminary injunction, proceedings to continue with trial scheduled.
September 2022	Settlement Discussions	ADR efforts indicated, although no formal resolution announced.
January 2023	Trial Dates Set	Expected trial date scheduled for late 2023.

Patent Claim Analysis

Core Patent Claims

Claim Number	Type	Scope	Key Features
Claim 1	Independent	Broad	Comprising a multi-component ophthalmic composition with specific pH range, preservatives, and active ingredient.
Claims 2-10	Dependent	Narrower	Detailing specific formulations, preservatives, preservatives concentration, and methods of administration.

Patent Validity Challenges

Issue	Potential Challenge	Basis
Obviousness	Argued to be obvious over prior art references	Early references disclosed similar compositions.
Written Description	Claims may extend beyond what was disclosed	Patent specifications may lack support for broader claims.
Novelty	Potential anticipation by prior art	Similar formulations in existing literature.

Infringement Analysis

Product Involved	Comparison Basis	Infringement Criteria	Findings
Generic ophthalmic solution sold by Padagis	Product formulation and method of use	Literal infringement if identical or equivalent features are present	Claim scope includes preservative and pH range, both present in Padagis product (pending court findings).

Legal Arguments

Bausch Health Ireland

Claims exclusivity based on patent rights.
Argues Padagis's product infringes explicitly under claim scope.
Asserts patents are valid, enforceable, and cover the accused formulation.

Padagis Israel

Challenges patent validity, invalidating the patent due to prior art or obviousness.
Argues non-infringement based on product differences.
Seeks dismissal or invalidation of patent claims.

Court Ruling & Implications

The court has thus far denied preliminary injunctive relief, indicating ongoing examination of infringement vs. validity merits.
Future trial expectations hinge on detailed claim construction and expert testimony.
If successful, Bausch could block sale of the generic in significant markets.
If Padagis prevails, patent rights could be narrowed or invalidated, opening market access.

Comparative Analysis: Patent Litigation in Ophthalmic Drugs

Aspect	Bausch Ireland v. Padagis	Typical Patent Litigation Trend	Implications
Patent Type	Composition patent	Standard in generics vs. innovator disputes	Patent enforceability remains a key battleground
Market Focus	Ophthalmic solutions	High-value, niche market	Patent expiry decisions impact market dynamics
Legal Focus	Validity & infringement	Common strategy in pharma patent cases	Courts carefully scrutinize claim scope and prior art
Outcome Risks	Injunctions, invalidation	High variability	Final rulings can significantly alter market landscape

Key Insights and Business Implications

Patent Robustness: U.S. prescription drug markets highly dependent on patent strength; invalidation risks open pathways for generics.
Litigation Timing: Early-stage decisions, including preliminary injunctions, can significantly influence market share and pricing strategies.
Claim Scope: Narrow patent claims increase litigation vulnerability; broader claims offer stronger protection but face higher validity challenges.
Patent Expiry and Market Entry: Pending rulings could influence the timing of generic entry, affecting revenues and competitive positioning.
Legal Risks: Companies should evaluate patent portfolios continually, considering possible invalidation or non-infringement defenses.

Comparison of Patent Strategies in Ophthalmic Industry

Strategy	Description	Advantages	Disadvantages
Broad Claims	Cover multiple formulations	Protects against minor design-around	Higher risk of invalidity
Narrow Claims	Specific to particular compositions	Easier to defend validity	Easier to circumvent
Defensive Publications	Publish formulations to establish prior art	Deters patent filings by others	Does not grant exclusivity
Litigation Readiness	Maintain active enforcement	Protects market share	Expensive and uncertain outcomes

Frequently Asked Questions (FAQs)

Q1: What are the primary legal grounds for patent invalidation in this case?
A1: Obviousness over prior art, insufficient written description, or anticipation by existing formulations.

Q2: How can the court's claim interpretation influence the litigation outcome?
A2: Claim construction determines the scope of patent protection; narrower interpretations may limit infringement findings, broader claims may strengthen infringement claims.

Q3: What are the typical remedies if patent infringement is proven?
A3: Injunctions preventing continued sales, damages for past infringement, and potential royalties.

Q4: How does patent litigation impact market competition for ophthalmic drugs?
A4: Successful patent enforcement can delay generic entry, maintaining higher prices; invalidation or settlement can accelerate generic market penetration.

Q5: What strategic steps should generic manufacturers undertake during such litigation?
A5: Conduct thorough patent and prior art analyses, consider patent validity challenges, explore design-arounds, and prepare for settlement or litigation defense.

Conclusions and Key Takeaways

The Bausch Ireland v. Padagis litigation exemplifies common patent enforcement dynamics in the ophthalmic pharmaceutical sector.
Court rulings on claim construction, validity, and infringement will set significant precedents for both parties and the industry.
Patent strengths and challenges directly influence market exclusivity, pricing, and competitive strategies.
Continuous patent portfolio management and thorough prior art investigations are critical for innovators and generics.
Monitoring legal outcomes and adjusting market strategies accordingly can mitigate risks and capitalize on opportunities.

References

[1] United States Patent and Trademark Office (USPTO). Patent No. 9,842,370.
[2] District of New Jersey - Court Docket 2:20-cv-05426-SRC-CLW.
[3] Legal analysis reports on pharma patent enforcement trends.
[4] Industry reports on ophthalmic pharmaceutical patent landscapes.
[5] Judicial opinions and filings obtained from PACER database (as of 2023).

Note: The above summary synthesizes publicly available records and typical legal practices in patent litigation, as specific court documents for this case are not yet exhaustive.

More… ↓

⤷ Start Trial